Childhood cancer survivors at higher risk of renal failure
9/27/2013
In a new study, adult survivors of childhood cancers who had certain chemotherapy treatments or kidney surgery had worse kidney function that did not recover over time. Researchers say this means they may be at higher risk for premature chronic renal failure...
Study of 'sister' stem cells uncovers new cancer clue
9/26/2013
Scientists have used a brand new technique for examining individual stem cells to uncover dramatic differences in the gene expression levels - which genes are turned 'up' or 'down' - between apparently identical 'sister' pairs. The research, published in Stem Cell Reports, was conducted and funded by The Institute of Cancer Research, London...
Merck Serono, the biopharmaceutical division of Merck, has announced the decision to continue clinical development of its investigational MUC1 antigen-specific cancer immunotherapy tecemotide (also known as L-BLP25) under a new Phase III trial called START2 for patients with unresectable, locally advanced Stage III non-small cell lung cancer (NSCLC)...
Potential to predict lung-cancer spread via MicroRNA-31
9/26/2013
Determining whether a patient's lung cancer has spread to nearby lymph nodes is critical for identifying the most effective therapy, but it usually requires surgery. A new study suggests, however, that measuring levels of a particular molecule in a sample of tumor tissue might accurately answer the question. Researchers at The Ohio State University Comprehensive Cancer Center - Arthur G...
Growing number of young adults with oropharyngeal cancer linked to HPV
9/26/2013
The human papillomavirus (HPV) may be to blame for the alarming increase of young adults with oropharyngeal cancer, according to researchers from Henry Ford Hospital in Detroit. The study reveals an overall 60 percent increase from 1973 and 2009 in cancers of the base of tongue, tonsils, soft palate and pharynx in people younger than age 45...
Merck Serono, the biopharmaceutical division of Merck, has announced the decision to continue clinical development of its investigational MUC1 antigen-specific cancer immunotherapy tecemotide (also known as L-BLP25) under a new Phase III trial called START2 for patients with unresectable, locally advanced Stage III non-small cell lung cancer (NSCLC)...
Research reveals why ibuprofen might stop cancers from developing
9/26/2013
Latest research by scientists at the University of Bath has shown why the anti-inflammatory drug ibuprofen might stop certain cancers from developing...
Potential to predict lung-cancer spread via MicroRNA-31
9/26/2013
Determining whether a patient's lung cancer has spread to nearby lymph nodes is critical for identifying the most effective therapy, but it usually requires surgery. A new study suggests, however, that measuring levels of a particular molecule in a sample of tumor tissue might accurately answer the question. Researchers at The Ohio State University Comprehensive Cancer Center - Arthur G...
Growing number of young adults with oropharyngeal cancer linked to HPV
9/26/2013
The human papillomavirus (HPV) may be to blame for the alarming increase of young adults with oropharyngeal cancer, according to researchers from Henry Ford Hospital in Detroit. The study reveals an overall 60 percent increase from 1973 and 2009 in cancers of the base of tongue, tonsils, soft palate and pharynx in people younger than age 45...
Biological risk factor pinpointed in obesity-related cancers
9/26/2013
It is estimated that over a third of the new cancer cases expected to occur in the U.S. in 2013 will be related to overweight or obesity, physical inactivity, and poor nutrition. Thanks to the work of one NYU Steinhardt researcher, we may better understand why...